Regeneron Pharmaceuticals said the company will vigorously defend federal charges of being involved in a kickback scheme to bolster sales of the blockbuster macular degeneration drug Eylea.

Less than a year after Sandoz, the generics arm of Novartis, vowed to fight allegations of being involved in a scheme to manipulate the price of generic drugs along with other drugmakers, the company changed course and agreed to pay a $195 million penalty to the U.S. government.

Hector Armando Kellum, a former senior executive with the Novartis subsidiary Sandoz, pleaded guilty for his role in a price-fixing scheme for generic drugs developed by his company.

The Federal Trade Commission filed a complaint in federal court against Vyera Pharmaceuticals, the company formerly known as Turing Pharmaceuticals that Martin Shkreli founded, alleging an “elaborate anticompetitive scheme to preserve a monopoly” on Daraprim.

John Kapoor, the founder and former chief executive officer of Insys Therapeutics, was sentenced to more than five years in federal prison for the role his company played in the opioid epidemic.

John Kapoor, the founder of Insys Therapeutics Inc., could be sentenced to several years in prison and ordered to forfeit up to $113 million for his role in a bribery and fraud scheme that contributed to the U.S. opioid crisis.

The first of the Insys Therapeutics executives found guilty of violating the Racketeer Influenced and Corrupt Organizations (RICO) Act in May 2019 was sentenced to 33 months in federal prison.

Days after agreeing to pay nearly $225 million in additional fines to the U.S. government for fraudulent marketing schemes to boost sales of the opioid Subsys, Insys Therapeutics filed for bankruptcy.

U.S. authorities said 24 defendants were charged in connection with one of the largest healthcare fraud schemes prosecuted by the federal government, involving telemedicine companies and resulting in more than $1.2 billion of losses.

The former chief executive of Insys Therapeutics Inc. agreed to plead guilty to participating in a scheme to bribe doctors.